NCT01124344View on ClinicalTrials.gov

Safety and Pharmacology Study of BMS-866949

PHASE1TerminatedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Major Depression
Interventions
DRUG

Placebo

Oral Solution, Oral, 0 mg, Once Daily, 14 days

DRUG

BMS-866949

Oral Solution, Oral, 3 mg, Once Daily, 14 days

DRUG

BMS-866949

Oral Solution, Oral, 10 mg, Once Daily, 14 days

DRUG

BMS-866949

Oral Solution, Oral, 30 mg, Once Daily, 14 days

DRUG

BMS-866949

Oral Solution, Oral, 45 mg, Once Daily, 14 days

DRUG

BMS-866949

Oral Solution, Oral, 60 mg, Once Daily, 14 days

DRUG

BMS-866949

Oral Solution, Oral, 90 mg, Once Daily, 14 days

DRUG

BMS-866949

Oral Solution, Oral, 3-60 mg, Once Daily, 14 days

Trial Locations (1)

751 23

Local Institution, Uppsala

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY